Atorvastatin in Moderate Active Crohns Disease

Phase 2

Completed

• Conditions: Crohns Disease

• Registration Number: NCT00454545
• Lead Sponsor: Skane University Hospital

Brief Summary

Open pilot study to collect information regarding the effect of atorvastatin on patients with active Crohns disease.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-10
• Study First Submitted: 2007-03-29
• Study First Submitted QC: 2007-03-29
• Study First Posted: 2007-03-30
• Status Verified: 2007-10
• Study Completion: 2007-10
• Last Update Submitted: 2007-10-18
• Last Update Posted: 2007-10-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

• Clinical diagnosis of Crohns disease
• C-reactive protein level > 2 mg/L in absence of an infection
• Fecal calprotectin > 250 mg/kg or CDAI > 150

Exclusion Criteria

• CDAI > 450
• Prednisolone dosage above 15 mg/day

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Inflammatory markers in plasma before and after treatment.

Secondary Outcome Measures

Name	Time	Method
Change in clinical activity index and mucosal inflammation after treatment.

Trial Locations

Locations (1)

Department of Medicine, Division of Gastroenterology and Hepatology; 🇸🇪 Malmö, Sweden